Biology of anti-angiogenic therapy-induced thrombotic microangiopathy

Vera Eremina, Susan E. Quaggin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.

Original languageEnglish (US)
Pages (from-to)582-590
Number of pages9
JournalSeminars in nephrology
Issue number6
StatePublished - Nov 2010


  • Anti-VEGF therapy
  • Endothelial cells
  • Glomerulus
  • TMA

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Biology of anti-angiogenic therapy-induced thrombotic microangiopathy'. Together they form a unique fingerprint.

Cite this